|
Oct 1
|
CureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firms
|
|
Aug 1
|
We Think CureVac (NASDAQ:CVAC) Can Afford To Drive Business Growth
|
|
Jul 11
|
CureVac Provides Trial Dates for Patent Litigation Against Pfizer, BioNTech
|
|
Jul 11
|
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
|
|
Jul 5
|
An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 47% Undervalued
|
|
Jun 24
|
CureVac Announces Voting Results of General Meeting
|
|
May 3
|
Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
|
|
Apr 27
|
CureVac Full Year 2023 Earnings: Misses Expectations
|
|
Apr 25
|
CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript
|
|
Apr 24
|
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
|
|
Apr 24
|
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
|
|
Apr 24
|
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
|
|
Apr 24
|
CureVac to cut costs in restructuring
|
|
Apr 23
|
CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30%
|
|
Apr 18
|
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
|
|
Apr 16
|
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
|
|
Apr 4
|
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
|
|
Jan 5
|
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
|
|
Dec 30
|
13 Best Get Rich Quick Stocks To Buy
|
|
Dec 22
|
These Analysts Just Made A Huge Downgrade To Their CureVac N.V. (NASDAQ:CVAC) EPS Forecasts
|